Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 52 articles: HTML format Text format

Single Articles

October 2019
1. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
   Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
   Lancet. 2019;394:1364.
   PubMed     Text format    
   
   
   September 2019
2. SCHMIDT E, Kasperkiewicz M, Joly P
   Pemphigus.
   Lancet. 2019;394:882-894.
   PubMed     Text format     Abstract available
   
   
   June 2019
3. DORNER T, Furie R
   Novel paradigms in systemic lupus erythematosus.
   Lancet. 2019;393:2344-2358.
   PubMed     Text format     Abstract available
   
   
   
4. DURCAN L, O'Dwyer T, Petri M
   Management strategies and future directions for systemic lupus erythematosus in adults.
   Lancet. 2019;393:2332-2343.
   PubMed     Text format     Abstract available
   
   
   May 2019
5. LUO J, Gonsalves G, Greene J
   Insulin for all: treatment activism and the global diabetes crisis.
   Lancet. 2019;393:2116-2117.
   PubMed     Text format    
   
   
   April 2019
6. ELAGHA A, Mohsen A
   Cardiac MRI clinches diagnosis of Libman-Sacks endocarditis.
   Lancet. 2019;393:e39.
   PubMed     Text format    
   
   
   
7. MCCALL B
   Alemtuzumab to be restricted pending review, says EMA.
   Lancet. 2019;393:1683.
   PubMed     Text format    
   
   
   March 2019
8. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
   Excess mortality and cardiovascular disease risk in type 1 diabetes.
   Lancet. 2019;393:985.
   PubMed     Text format    
   
   
   
9. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
   Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
   Lancet. 2019;393:985-986.
   PubMed     Text format    
   
   
   
10. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    
    
    
    February 2019
11. YUAN K, Huang G, Sang X, Xu A, et al
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2019;393:402.
    PubMed     Text format    
    
    
    
12. WALLACE DJ, Furie RA, Tanaka Y, de Bono S, et al
    Baricitinib for systemic lupus erythematosus - Authors' reply.
    Lancet. 2019;393:402-403.
    PubMed     Text format    
    
    
    January 2019
13. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.
    PubMed     Text format    
    
    
    December 2018
14. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed     Text format    
    
    
    October 2018
15. COSTEDOAT-CHALUMEAU N, Houssiau FA
    Ustekinumab: a promising new drug for SLE?
    Lancet. 2018;392:1284-1286.
    PubMed     Text format    
    
    
    
16. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed     Text format    
    
    
    
17. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Text format     Abstract available
    
    
    September 2018
18. VAN VOLLENHOVEN RF, Hahn BH, Tsokos GC, Wagner CL, et al
    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32167.
    PubMed     Text format     Abstract available
    
    
    
19. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.
    PubMed     Text format    
    
    
    
20. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.
    PubMed     Text format    
    
    
    
21. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.
    PubMed     Text format    
    
    
    
22. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Text format     Abstract available
    
    
    
23. PERL A, Lai ZW, Kelly R, Faraone SV, et al
    Sirolimus for systemic lupus erythematosus - Authors' reply.
    Lancet. 2018;392:734.
    PubMed     Text format    
    
    
    
24. HU HQ, Lee FJ, Garsia R
    Sirolimus for systemic lupus erythematosus.
    Lancet. 2018;392:733-734.
    PubMed     Text format    
    
    
    August 2018
25. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed     Text format    
    
    
    
26. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available
    
    
    July 2018
27. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    PubMed     Text format     Abstract available
    
    
    
28. MUCKE J, Schneider M
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2018;392:190-192.
    PubMed     Text format    
    
    
    June 2018
29. XIAO F, Tian X, Wang XF
    Antiphospholipid syndrome causing reversible internal carotid artery thrombosis.
    Lancet. 2018;391:2641.
    PubMed     Text format    
    
    
    
30. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Text format     Abstract available
    
    
    March 2018
31. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed     Text format    
    
    
    
32. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed     Text format    
    
    
    
33. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed     Text format    
    
    
    
34. METZ LM, Liu WQ
    Effective treatment of progressive MS remains elusive.
    Lancet. 2018;391:1239-1240.
    PubMed     Text format    
    
    
    
35. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
    Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
    PubMed     Text format     Abstract available
    
    
    
36. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
    Multiple sclerosis.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
    PubMed     Text format     Abstract available
    
    
    
37. THE LANCET
    End of the road for daclizumab in multiple sclerosis.
    Lancet. 2018;391:1000.
    PubMed     Text format    
    
    
    
38. LAI ZW, Kelly R, Winans T, Marchena I, et al
    Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30485.
    PubMed     Text format     Abstract available
    
    
    
39. FERNANDEZ DR, Crow MK
    CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematous.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30544.
    PubMed     Text format    
    
    
    February 2018
40. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed     Text format    
    
    
    
41. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Text format     Abstract available
    
    
    January 2018
42. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed     Text format    
    
    
    December 2017
43. TSUDA K, Tanimoto T, Mori J, Kosugi K, et al
    Targeted-release budesonide therapy for IgA nephropathy.
    Lancet. 2017;390:2625.
    PubMed     Text format    
    
    
    
44. FELLSTROM B, Barratt J, Floge J, Jardine A, et al
    Targeted-release budesonide therapy for IgA nephropathy - Authors' reply.
    Lancet. 2017;390:2625-2626.
    PubMed     Text format    
    
    
    October 2017
45. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
    Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
    Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
    PubMed     Text format     Abstract available
    
    
    
46. RUBIN R
    Mary Crow: leader in research on systemic lupus erythematosus.
    Lancet. 2017;390:1636.
    PubMed     Text format    
    
    
    September 2017
47. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed     Text format    
    
    
    
48. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Text format     Abstract available
    
    
    March 2017
49. WYATT RJ
    Are we ready for targeted therapy for IgA nephropathy?
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30820.
    PubMed     Text format    
    
    
    
50. FELLSTROM BC, Barratt J, Cook H, Coppo R, et al
    Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30550.
    PubMed     Text format     Abstract available
    
    
    December 2016
51. EL-KHATIB FH, Balliro C, Hillard MA, Magyar KL, et al
    Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    Lancet. 2016 Dec 20. pii: S0140-6736(16)32567.
    PubMed     Text format     Abstract available
    
    
    September 2016
52. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Lancet. 2016 Sep 9. pii: S0140-6736(16)31535.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: